Article written by Bruce Sylvester
In a study published on June 2, 2020 in Diabetologia, researchers reported that ertugliflozin preserves renal function in type 2 diabetics with baseline albuminuria, protecting renal function in these patients with diabetes while controlling blood sugar.
“Ertugliflozin reduced eGFR at week 6, consistent with the known pharmacodynamic effects of SGLT2 inhibitors on renal function,” the authors said. “Over 104 weeks, eGFR values returned to baseline and were higher with ertugliflozin compared with non-ertugliflozin treatment, even though changes in HbA1c did not differ between the groups. Ertugliflozin reduced UACR in patients with baseline albuminuria,” they added.\
As background, they noted that ertugliflozin is a selective SGLT2 inhibitor approved for adults with type 2 diabetes mellitus as a glucose-lowering agent. It is being evaluated in the ongoing cardiovascular outcome trial eValuation of ERTugliflozin effIcacy and Safety (VERTIS) CV.
In this new analysis, mean baseline eGFR was 88.2 ml min−1 and mean baseline urine albumin/creatinine ratio was 1.31 mg/mmol.
At week 6, the changes in eGFR from baseline were −2.3, −2.7 and −0.7 ml min−1 for the ertugliflozin 5 mg, ertugliflozin 15 mg and non-ertugliflozin groups, respectively.
After 6 weeks eGFR in the ertugliflozin groups increased gradually, and it decreased in the non-ertugliflozin cohort.
At week 104, changes in eGFR from baseline were −0.2, 0.1 and −2.0 ml min−1 for the ertugliflozin 5 mg, ertugliflozin 15 mg and non-ertugliflozin groups, respectively.
Notably, among 415 subjects (21.4% of the total group of subjects) with albuminuria at baseline, those in the ertugliflozin groups achieved greater reductions in urine albumin/creatinine ratio at all measured time points up to week 104.
The authors said that their findings suggest preservation of renal function with ertugliflozin treatment among people with type 2 diabetes and baseline albuminuria.